Association between diabetic peripheral neuropathy and sarcopenia: A systematic review and meta‐analysis

Wannarong, Thapat; Sukpornchairak, Persen; Naweera, Weerakit; Geiger, Christopher D.; Ungprasert, Patompong

doi:10.1111/ggi.14462

Cited by 10 publications

(7 citation statements)

References 24 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcopenia is more prevalent in patients with chronic diseases, such as T2D, indicating that the age-related decline in skeletal muscle performance is faster than in healthy individuals [ 4 , 5 ]. Poor glucose control, longer diabetes evolution, and the presence of chronic diabetes-related complications also increase the risk of sarcopenia in T2D [ 6 , 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age

Lisco,

Disoteo,

De Tullio

et al. 2023

Nutrients

View full text Add to dashboard Cite

Sarcopenia is an age-related clinical complaint characterized by the progressive deterioration of skeletal muscle mass and strength over time. Type 2 diabetes (T2D) is associated with faster and more relevant skeletal muscle impairment. Both conditions influence each other, leading to negative consequences on glycemic control, cardiovascular risk, general health status, risk of falls, frailty, overall quality of life, and mortality. PubMed/Medline, Scopus, Web of Science, and Google Scholar were searched for research articles, scientific reports, observational studies, clinical trials, narrative and systematic reviews, and meta-analyses to review the evidence on the pathophysiology of di-abetes-induced sarcopenia, its relevance in terms of glucose control and diabetes-related outcomes, and diagnostic and therapeutic challenges. The review comprehensively addresses key elements for the clinical definition and diagnostic criteria of sarcopenia, the pathophysiological correlation be-tween T2D, sarcopenia, and related outcomes, a critical review of the role of antihyperglycemic treatment on skeletal muscle health, and perspectives on the role of specific treatment targeting myokine signaling pathways involved in glucose control and the regulation of skeletal muscle metabolism and trophism. Prompt diagnosis and adequate management, including lifestyle inter-vention, health diet programs, micronutrient supplementation, physical exercise, and pharmaco-logical treatment, are needed to prevent or delay skeletal muscle deterioration in T2D.

show abstract

Section: Introductionmentioning

confidence: 99%

Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age

Lisco,

Disoteo,

De Tullio

et al. 2023

Nutrients

View full text Add to dashboard Cite

show abstract

“…However, due to the change and combined use of different medicines, the influence of drugs was hard to eliminate. Besides, although diabetic kidney disease and diabetic retinopathy were the risk factors of DPN in other studies [ 4 ], the sample size and criteria excluding uremia decreased the effect.…”

Section: Discussionmentioning

confidence: 88%

“…The same operator used the ultrasound device (Esaote, S.p.A, Italia, MyLab™Twice) equipped with a LA523 linear array transducer (3)(4)(5)(6)(7)(8)(9)(10)(11)(12) to obtain images of muscles. The operator followed the pattern of musculoskeletal scanning but adjusted the depth and focus region based on different situations.…”

Section: Muscular Ultrasound Measurementsmentioning

confidence: 99%

“…Diabetes speeds up muscular atrophy through oxidative stress and inflammation pathway [ 3 ]. A meta-analyzed research including associated cross-sectional articles based on dual-energy X-ray absorptiometry (DXA) showed that the connection between DPN and sarcopenia might be statistically significant with the pooled OR of 1.62 (95% CI: 1.30-2.02, I 2 0%) [ 4 ]. One found that increased muscle mass index predicted improvement of partial motor and sensory nerve conduction velocity among T2DM male patients in the follow-up period [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Relationship between Muscle Ultrasound Parameters and Diabetic Peripheral Neuropathy among Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Zhong,

Liu,

Lin

2023

Journal of Diabetes Research

View full text Add to dashboard Cite

Background. Muscle dysfunction is an early complication of diabetic peripheral neuropathy (DPN). As a convenient and low-cost tool, muscle ultrasound has been used to assess muscle quality and muscle mass. However, the relationship between different muscle ultrasound parameters and DPN is unclear. Objectives. This study was designed to investigate the relationship between ultrasound parameters of different muscles and DPN among patients with type 2 diabetes mellitus, including the rectus femoris (RF), tibialis anterior (TA), and medial head of gastrocnemius (MG). Materials and Methods. The research enrolled 90 patients with type 2 diabetes mellitus (T2DM). All images were attained from both sides. Muscle measurements contained muscle thickness (MT), cross-sectional area (CSA), echo intensity (EI), and corrected EI. The binary logistic regression and multiple linear regression were used to investigate the association between muscle ultrasound parameters and DPN or vibration perception threshold (VPT). Results. EI, corrected EI, MT of MG, and EI of TA were associated with DPN separately after adjusting other clinical variates. Among these muscle parameters, the EI of MG had a better predictive value (OR: 1.114, 95% CI: 1.039, 1.196) of DPN. Combined with CSA of RF, peripheral artery disease (PAD), and sex, the corrected EI of MG was associated with the vibration perception threshold (VPT) (standard β = 0.242 , p < 0.001 ), better than the EI of MG (standard β = 0.215 , p = 0.002 ). Conclusions. MG (MT, EI, and corrected EI) and TA (EI) were associated with DPN, respectively. CSA of RF and corrected EI or EI of MG combined with PAD and sex were associated with VPT significantly, which supported that muscle ultrasound might be a substantial quantitative tool for detecting the exercise benefits for DPN.

show abstract

“…In general, while atherosclerosis can lead to reduced oxygenation of muscle tissue, a study has also proposed an insulin‐dependent vasodilatation mechanism, which is necessary for muscle capillary recruitment during exercise 34 . Diabetic neuropathy leads to a premature axonal loss of motor units, which can impair muscle strength and cause muscle atrophy 35 . In conjunction with neuropathy, people with T2D exhibit a downregulated expression of neurotrophin‐3, a critical growth factor for neurogenesis 36 …”

Section: Changes In Muscle Architecturementioning

confidence: 99%

Pathophysiological interactions between sarcopenia and type 2 diabetes: A two‐way street influencing diagnosis and therapeutic options

Tack,

De Cock,

Dirinck

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

This review will try to elucidate the interconnected pathophysiology of sarcopenia and type 2 diabetes (T2D) and will try to identify a common pathway to explain their development. To this end, the PubMed and Scopus databases were searched for articles published about the underlying pathophysiology, diagnosis and treatment of both sarcopenia and T2D. The medical subject heading (MeSH) terms ‘sarcopenia’ AND ‘diabetes mellitus’ AND (‘physiopathology’ OR ‘diagnosis’ OR ‘therapeutics’ OR ‘aetiology’ OR ‘causality’) were used. After screening, 32 papers were included. It was evident that sarcopenia and T2D share multiple pathophysiological mechanisms. Common changes in muscle architecture consist of a shift in myocyte composition, increased myosteatosis and a decreased capacity for muscle regeneration. Further, both diseases are linked to an imbalance in myokine and sex hormone production. Chronic low‐grade inflammation and increased levels of oxidative stress are also known pathophysiological contributors. In the future, research efforts should be directed towards discovering common checkpoints in the development of T2D and sarcopenia as possible shared therapeutic targets for both diseases. Current treatment for T2D with biguanides, incretins and insulin may already convey a protective effect on the development of sarcopenia. Furthermore, attention should be given to early diagnosis of sarcopenia within the population of people with T2D, given the sizeable physical and medical burden it encompasses. A combination of simple diagnostic techniques could be used at regular diabetes check‐ups to identify sarcopenia at an early stage and start lifestyle modifications and treatment as soon as possible.

show abstract

Association between diabetic peripheral neuropathy and sarcopenia: A systematic review and meta‐analysis

Cited by 10 publications

References 24 publications

Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age

Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age

The Relationship between Muscle Ultrasound Parameters and Diabetic Peripheral Neuropathy among Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Pathophysiological interactions between sarcopenia and type 2 diabetes: A two‐way street influencing diagnosis and therapeutic options

Contact Info

Product

Resources

About